Shares of Nuformix plc (LON:NFX – Get Free Report) traded up 12.8% on Wednesday . The stock traded as high as GBX 0.22 and last traded at GBX 0.22. 29,756,219 shares were traded during mid-day trading, a decline of 8% from the average session volume of 32,172,387 shares. The stock had previously closed at GBX 0.20.
Nuformix Trading Up 3.6%
The firm has a market capitalization of £4.26 million, a price-to-earnings ratio of -0.51 and a beta of 1.22. The company has a fifty day moving average price of GBX 0.26 and a 200-day moving average price of GBX 0.22.
Nuformix (LON:NFX – Get Free Report) last released its quarterly earnings data on Tuesday, January 27th. The company reported GBX (0.04) EPS for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Featured Stories
- Five stocks we like better than Nuformix
- [No Brainer Gold Play]: “Show me a better investment.”
- This $15 Stock Could Go Down as the #1 Stock of 2026
- What a Former CIA Agent Knows About the Coming Collapse
- The day the gold market broke
- Ray Dalio Says Buy Gold. I Say Get Paid Every Month From It
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
